Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Finkener

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Multiple Sclerosis and Related Disorders|December 22, 2022
Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional studySebastian Finkener, Lutz Achtnichts, Michaela Cervenakova, et al.
Clinical Parkinsonism & Related Disorders|March 29, 2022
Recognizing myorhythmia 4 months after stroke - A teaching videoSebastian Finkener, Tobias Piroth, Magdalena Högg, et al.
BMC Infectious Diseases|September 4, 2024
Transfusion-related acute lung injury (TRALI) following intravenous immunoglobulin infusion in a rituximab immunosuppressed patient with long-shedding SARS-CoV-2Ganna Degtiarova, Anna Conen, Alexander Klarer, et al.
Advances in Therapy|March 10, 2026
The Treatment of Antibody-Mediated Encephalitis: Current, Future Therapies, Unmet Need and Patient ManagementSmaila Mulic-Al Bunni, Markus Gschwind, Sebastian Finkener, et al.
Clinical Chemistry and Laboratory Medicine|December 26, 2025
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemse, Sofia Sandgren, Pascal Benkert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 23, 2026
Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and BeyondJohanna Oechtering, Sabine Anna Schaedelin, Aleksandra Maleska Maceski, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis and Related Disorders|December 22, 2022
Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional studySebastian Finkener, Lutz Achtnichts, Michaela Cervenakova, et al.
Clinical Parkinsonism & Related Disorders|March 29, 2022
Recognizing myorhythmia 4 months after stroke - A teaching videoSebastian Finkener, Tobias Piroth, Magdalena Högg, et al.
BMC Infectious Diseases|September 4, 2024
Transfusion-related acute lung injury (TRALI) following intravenous immunoglobulin infusion in a rituximab immunosuppressed patient with long-shedding SARS-CoV-2Ganna Degtiarova, Anna Conen, Alexander Klarer, et al.
Advances in Therapy|March 10, 2026
The Treatment of Antibody-Mediated Encephalitis: Current, Future Therapies, Unmet Need and Patient ManagementSmaila Mulic-Al Bunni, Markus Gschwind, Sebastian Finkener, et al.
Clinical Chemistry and Laboratory Medicine|December 26, 2025
Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controlsEline A J Willemse, Sofia Sandgren, Pascal Benkert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 23, 2026
Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and BeyondJohanna Oechtering, Sabine Anna Schaedelin, Aleksandra Maleska Maceski, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Pageof 2